Zobrazeno 1 - 10
of 38
pro vyhledávání: '"S Rhinehart"'
Autor:
Satish K, Garg, George, Grunberger, Ruth, Weinstock, Margaret L, Lawson, Irl B, Hirsch, Linda A, DiMeglio, Rodica, Pop-Busui, Athena, Philis-Tsimikas, Mark, Kipnes, David R, Liljenquist, Ronald L, Brazg, Yogish C, Kudva, Bruce A, Buckingham, Janet B, McGill, Anders L, Carlson, Amy B, Criego, Mark P, Christiansen, Kevin B, Kaiserman, Kurt J, Griffin, Greg P, Forlenza, Bruce W, Bode, Robert H, Slover, Ashleigh, Keiter, Chenxiao, Ling, Briggitte, Marinos, Toni L, Cordero, John, Shin, Scott W, Lee, Andrew S, Rhinehart, Robert A, Vigersky, Mary, Jane Clifton
Publikováno v:
Diabetes Technology & Therapeutics. 25:1-12
Autor:
Ron Brazg, Satish K. Garg, Anuj Bhargava, James R. Thrasher, Kashif Latif, Bruce W. Bode, Timothy S. Bailey, Barry S. Horowitz, Arvind Cavale, Yogish C. Kudva, Kevin B. Kaiserman, George Grunberger, John Chip Reed, Sarnath Chattaraj, Gina Zhang, John Shin, Vivian Chen, Scott W. Lee, Toni L. Cordero, Andrew S. Rhinehart, Robert A. Vigersky, Bruce A. Buckingham
Publikováno v:
Diabetes Technology & Therapeutics. 24:535-543
Autor:
Richard A.M. Jonkers, Robert A. Vigersky, John H. Shin, Toni L. Cordero, Anirban Roy, Dorothy I. Shulman, Rodica Pop-Busui, Melissa Vella, Athena Philis-Tsimikas, Mark Kipnes, Benyamin Grosman, John C. Reed, Xiaoxiao Chen, Andrew S. Rhinehart, Kevin B. Kaiserman, Mark P. Christiansen, Anders L. Carlson, James Thrasher, Bruce W. Bode, Robert H. Slover, Jennifer L. Sherr, Scott W. Lee, Ron Brazg, Satish K. Garg, David R. Lilenquist
Publikováno v:
Diabetes Technology & Therapeutics. 24:178-189
Introduction: This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adol...
Autor:
JOHN SHIN, ARCELIA ARRIETA, JAVIER CASTAÑEDA, TONI L. CORDERO, ANDREW S. RHINEHART, ROBERT A. VIGERSKY
Publikováno v:
Diabetes. 71
Objective: Since 2021, the MiniMed™ 780G advanced hybrid closed-loop system with the non-adjunctive Guardian™ 4 sensor, that does not require calibration, has been commercially available in Europe. In this study, the real-world glycemic outcomes
Autor:
BRUCE W. BODE, TIMOTHY S. BAILEY, KRISTIN N. CASTORINO, MARK P. CHRISTIANSEN, SATISH K. GARG, KEVIN B. KAISERMAN, DAVID R. LILJENQUIST, DOROTHY I. SHULMAN, ROBERT H. SLOVER, JOHN SHIN, FEN PENG, SUIYING HUANG, ANDREW S. RHINEHART, ROBERT A. VIGERSKY
Publikováno v:
Diabetes. 71
Objective: A CGM sensor that is disposable and requires no calibration may make glucose management easier for people living with diabetes. The present study reports on the interim analysis of a new disposable zero-calibration sensor in adults and you
Autor:
ROBERT A. VIGERSKY, BRUCE W. BODE, RONALD L. BRAZG, BRUCE A. BUCKINGHAM, ANDERS L. CARLSON, KEVIN B. KAISERMAN, MARK KIPNES, DAVID R. LILJENQUIST, ATHENA PHILIS-TSIMIKAS, CATHERINE PIHOKER, RODICA POP-BUSUI, JOHN REED, JENNIFER SHERR, DOROTHY I. SHULMAN, ROBERT H. SLOVER, JAMES THRASHER, XIAOXIAO CHEN, MARGARET LIU, TONI L. CORDERO, MELISSA VELLA, ANDREW S. RHINEHART, JOHN SHIN
Publikováno v:
Diabetes. 71
Background: Safety and effectiveness outcomes of individuals using the MiniMed™ 780G system with the no-calibration Guardian™ 4 sensor during the first three months of use were analyzed. Methods: Participants (N=176, aged 7-75 years) with T1D use
Autor:
ROBERT A. VIGERSKY, JAVIER CASTAÑEDA, ARCELIA ARRIETA, TONI L. CORDERO, ANDREW S. RHINEHART, JOHN SHIN
Publikováno v:
Diabetes. 71
Objective: The MiniMed™ 780G system with the adjunctive Guardian™ sensor 3 that requires calibration has been commercially available in Europe, since October 2020. Since October 2021, the system has been available with the non-adjunctive Guardian
Autor:
Margaret Liu, Suiying Huang, John H. Shin, Xiaoxiao Chen, Andrew S. Rhinehart, Robert A. Vigersky, Toni L. Cordero
Publikováno v:
Diabetes. 70
Background: The Medtronic MiniMed™ AHCL system that autocorrects to 120mg/dL every five minutes and has an automated basal target of 100mg/dL or 120mg/dL has demonstrated improved A1C and time in range1,2 or improved time in closed-loop control,3 c
Autor:
Neha J. Parikh, Anirban Roy, Ronald L. Brazg, James Thrasher, Bruce W. Bode, Andrew S. Rhinehart, Robert H. Slover, Lintereur Louis J, David R. Liljenquist, Scott W. Lee, Xiaoxiao Chen, Mark P. Christiansen, John H. Shin, Dorothy I. Shulman, Rodica Pop-Busui, Athena Philis-Tsimikas, Margaret Liu, Robert A. Vigersky, Benyamin Grosman, Anders L. Carlson, Jennifer L. Sherr, Mark Kipnes, Satish K. Garg, Di Wu, Fen Peng, Kamalpreet K. Singh, Kevin B. Kaiserman
Publikováno v:
Diabetes. 69
Background: Automated insulin delivery systems improve glycemic control including time spent in, below and above range (TIR, TBR and TAR, respectively) in people with T1D. A next generation system, the MiniMedTM AHCL system, that offers a target set
Publikováno v:
Journal of the Endocrine Society
BACKGROUND On average, 1 of every 3 hospitalized patients — the majority with diabetes — requires insulin to control blood glucose during their stay. Although widely prescribed and absolutely necessary, insulin is inherently dangerous: 50% of all